Marinus Pharmaceuticals Announced Topline Results From Phase 3 RAISE Trial Of Intravenous Ganaxolone For Refractory Status Epilepticus, The Trial Met The First Co-primary Endpoint But Did Not Meet The Second Co-primary Endpoint
$MRNS
Biotechnology: Pharmaceutical Preparations
Health Care
- RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population
- The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia
- Marinus will continue to prioritize the ZTALMY franchise and expansion opportunities in highly refractory, chronic epilepsies with Phase 3 TrustTSC topline data expected in the first half of Q4 2024
- As a result of recently implemented cost reduction plans and financing activity, the Company projects cash runway into Q2 2025